{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:37:26Z","timestamp":1785609446993,"version":"3.56.0"},"reference-count":30,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,5]]},"abstract":"<jats:p>Human infection with <jats:italic>Fasciola hepatica<\/jats:italic> leads to obstruction of the common bile duct by adult worms and disease characterized by biliary colic, epigastric pain, and nausea. Recommended treatment is a single dose of triclabendazole (TCBZ) (10 mg\/kg). Because in the 1990s the Bolivian Altiplano bordering Lake Titicaca was thought to have the highest prevalence of human fascioliasis worldwide, the Bolivian Ministry of Health instituted TCBZ mass drug administration (MDA). From 2008 to 2016 (excepting 2015), one dose of 250 mg was administered, usually in September\/October, to each resident of highly endemic regions willing to participate. This is apparently the first reported use of MDA for <jats:italic>Fasciola<\/jats:italic>. The proportion of persons in key regions receiving TCBZ MDA was 87% in 2016. In 2017, we resurveyed key regions, and found that the MDA program had been dramatically successful. Whereas <jats:italic>Fasciola<\/jats:italic> prevalence was reported as 26.9% in Huacullani\/Tiahuanaco and 12.6% in Batallas in 1999, there was 0.7% prevalence in Huacullani\/Tiahuanaco and 1% in Batallas in 2017. However, lessons from schistosomiasis control efforts suggest that for sustained control of <jats:italic>Fasciola<\/jats:italic> infection, <jats:italic>Fasciola<\/jats:italic> MDA needs to be maintained and coupled with measures to control infection in the intermediary snail and in the animal hosts of <jats:italic>F. hepatica<\/jats:italic>.<\/jats:p>","DOI":"10.4269\/ajtmh.19-0060","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T07:01:05Z","timestamp":1558422065000},"page":"1494-1497","source":"Crossref","is-referenced-by-count":13,"title":["Mass Drug Administration of Triclabendazole for Fasciola Hepatica in Bolivia"],"prefix":"10.4269","volume":"100","author":[{"given":"Sergio","family":"Mollinedo","sequence":"first","affiliation":[{"name":"Instituto de Salud y Medio Ambiente (ISMA), La Paz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"FUNDERMA (Fundaci\u00f3n Nacional de Dermatolog\u00eda), Santa Cruz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Azurduy","sequence":"additional","affiliation":[{"name":"Servicio Departamental de Salud (SEDES), La Paz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Valle","sequence":"additional","affiliation":[{"name":"Servicio Departamental de Salud (SEDES), La Paz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Salas","sequence":"additional","affiliation":[{"name":"Servicio Departamental de Salud (SEDES), La Paz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoraida","family":"Mollinedo","sequence":"additional","affiliation":[{"name":"Universidad Amaz\u00f3nica de Pando, Pando, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Soto","sequence":"additional","affiliation":[{"name":"FUNDERMA (Fundaci\u00f3n Nacional de Dermatolog\u00eda), Santa Cruz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleye F.","family":"Villarroel","sequence":"additional","affiliation":[{"name":"Instituto de Salud y Medio Ambiente (ISMA), La Paz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Ransom","sequence":"additional","affiliation":[{"name":"Fast-Track Drugs and Biologics, North Potomac, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Chesapeake Therapeutics, Owings Mills, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Berman","sequence":"additional","affiliation":[{"name":"AB Foundation, North Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Soto","sequence":"additional","affiliation":[{"name":"FUNDERMA (Fundaci\u00f3n Nacional de Dermatolog\u00eda), Santa Cruz, Bolivia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Parasites\u2014Fascioliasis (Fasciola Infection): Biology","author":"Centers for Disease Control and Prevention (CDC)","year":"2018"},{"key":"b2","series-title":"Parasites\u2014Fascioliasis (Fasciola Infection): Epidemiology and Risk Factors","author":"Centers for Disease Control and Prevention (CDC)","year":"2018"},{"key":"b3","series-title":"Trav Med Infect Dis","first-page":"636","article-title":"Fascioliasis: a worldwide parasitic disease of importance in travel medicine","volume":"12","author":"Ashrafi","year":"2014"},{"key":"b4","series-title":"J Helminthol","first-page":"207","article-title":"Epidemiology of fascioliasis in human endemic areas","volume":"79","author":"Mas-Coma","year":"2005"},{"key":"b5","series-title":"Report of the WHO Informal Meeting on Use of Triclabendazole in Fascioliasis Control","author":"World Health Organization (WHO)","year":"2006"},{"key":"b6","series-title":"Trop Med Int Health","first-page":"695","article-title":"A population-based coprological study of human fascioliasis in a hyperendemic area of the Bolivian Altiplano","volume":"2","author":"Esteban","year":"1997"},{"key":"b7","series-title":"Trop Med Int Health","first-page":"454","article-title":"The northern Bolivian Altiplano: a region highly endemic for human fascioliasis","volume":"4","author":"Mas-Coma","year":"1999"},{"key":"b8"},{"key":"b9","series-title":"Parasitology","first-page":"S115","article-title":"Fasciola hepatica and lymnaeid snails occurring at very high altitude in South America","volume":"123","author":"Mas-Coma","year":"2001"},{"key":"b10","series-title":"Ann Parasitol","first-page":"283","article-title":"Evidence of Fasciola spp. resistance to albendazole, triclabendazole and bromofenofos in water buffaloes (Bubalus bubalis)","volume":"61","author":"Venturina","year":"2015"},{"key":"b11","series-title":"Int J Parasitol Drugs Drug Resist","first-page":"141","article-title":"Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test","volume":"6","author":"Novobilsk\u00fd","year":"2016"},{"key":"b12","series-title":"Gastroenterol Clin Biol","first-page":"513","article-title":"Human fascioliasis: cure by mebendazole? A case report","volume":"10","author":"Dugernier","year":"1986"},{"key":"b13","series-title":"Pathog Glob Health","first-page":"200","article-title":"Prevalence of soil-transmitted helminths after mass albendazole administration in an indigenous community of the Manu jungle in Peru","volume":"108","author":"Cabada","year":"2014"},{"key":"b14","series-title":"Am J Trop Med Hyg","first-page":"481","article-title":"Burden of Fasciola hepatica infection among children from Paucartambo in Cusco, Peru","volume":"86","author":"Lopez","year":"2012"},{"key":"b15","series-title":"Am J Trop Med Hyg","first-page":"989","article-title":"Fascioliasis and eosinophilia in the highlands of Cuzco, Peru and their association with water and socioeconomic factors","volume":"91","author":"Cabada","year":"2014"},{"key":"b16","series-title":"Acta Trop","first-page":"295","article-title":"The school health programme in Behera: an integrated helminth control programme at governorate level in Egypt","volume":"86","author":"Curtale","year":"2003"},{"key":"b17","series-title":"Trans R Soc Trop Med Hyg","first-page":"599","article-title":"Control of human fascioliasis by selective chemotherapy: design, cost and effect of the first public health, school-based intervention implemented in endemic areas of the Nile Delta, Egypt","volume":"99","author":"Curtale","year":"2005"},{"key":"b18","series-title":"Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases","author":"WHO","year":"2012"},{"key":"b19","series-title":"Am J Trop Med Hyg","first-page":"1397","article-title":"Impact of four years of annual mass drug administration on prevalence and intensity of schistosomiasis among primary and high school children in western Kenya: a repeated cross-sectional study","volume":"98","author":"Abudho","year":"2018"},{"key":"b20","series-title":"Am J Trop Med Hyg","first-page":"1810","article-title":"Defining persistent hotspots: areas that fail to decrease meaningfully in prevalence after multiple years of mass drug administration with praziquantel for control of schistosomiasis","volume":"97","author":"Kittur","year":"2017"},{"key":"b21","series-title":"Infect Dis Poverty","first-page":"8","article-title":"Schistosomiasis and soil-transmitted helminthiasis in Rwanda: an update on their epidemiology and control","volume":"6","author":"Rujeni","year":"2017"},{"key":"b22","series-title":"J Infect Dis","first-page":"283","article-title":"Can mass drug administration lead to the sustainable control of schistosomiasis?","volume":"211","author":"Ross","year":"2015"},{"key":"b23","series-title":"Parasit Vectors","first-page":"441","article-title":"Mass drug administration and the sustainable control of schistosomiasis: an evaluation of treatment compliance in the rural Philippines","volume":"11","author":"Inobaya","year":"2018"},{"key":"b24","series-title":"PLoS Negl Trop Dis","first-page":"e3221","article-title":"No apparent reduction in schistosome burden or genetic diversity following four years of school-based mass drug administration in Mwea, central Kenya, a heavy transmission area","volume":"8","author":"Lelo","year":"2014"},{"key":"b25","series-title":"Infect Dis Poverty","first-page":"42","article-title":"Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies","volume":"6","author":"Tchuem Tchuent\u00e9","year":"2017"},{"key":"b26","series-title":"PLoS Negl Trop Dis","first-page":"e1720","article-title":"Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano","volume":"6","author":"Villegas","year":"2012"},{"key":"b27","series-title":"Rev Soc Bras Med Trop","first-page":"445","article-title":"Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children","volume":"48","author":"Maco","year":"2015"},{"key":"b28","series-title":"Trends Parasitol","first-page":"458","article-title":"Current threat of triclabendazole resistance in Fasciola hepatica","volume":"32","author":"Kelley","year":"2016"},{"key":"b29","series-title":"PLoS Negl Trop Dis","first-page":"e0004361","article-title":"Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: a case series","volume":"10","author":"Cabada","year":"2016"},{"key":"b30","series-title":"Curr Opin Infect Dis","first-page":"409","article-title":"Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection","volume":"31","author":"Webb","year":"2018"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/100\/6\/article-p1494.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/100\/6\/article-p1494.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/100\/6\/article-p1494.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T21:16:07Z","timestamp":1722460567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/100\/6\/article-p1494.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":30,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.19-0060","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]}}}